Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial

•Escitalopram is as effective as sertraline in treatment of obsessions in patients with obsessive compulsive disorder (OCD).•Escitalopram is as effective as sertraline in treatment of compulsions in patients with OCD.•Overall, escitalopram and sertraline have comparable efficacy in management of pat...

Full description

Saved in:
Bibliographic Details
Published in:Asian journal of psychiatry 2018-12, Vol.38, p.92-95
Main Authors: Mowla, Arash, Modarresi, Farzaneh, Dastgheib, Seyed Ali
Format: Article
Language:English
Subjects:
Escitalopram
Obsessive compulsive disorder
Sertraline
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Escitalopram is as effective as sertraline in treatment of obsessions in patients with obsessive compulsive disorder (OCD).•Escitalopram is as effective as sertraline in treatment of compulsions in patients with OCD.•Overall, escitalopram and sertraline have comparable efficacy in management of patients with OCD.•Escitalopram is safe in treatment of OCD. Escitalopram has some unique features among selective serotonin reuptake inhibitors. The aim of this survey is to compare the efficacy of escitalopram with sertraline on obsessive and compulsive symptoms in patients with Obsessive Compulsive Disorder (OCD). In this 12-week double blind controlled randomized clinical trial, 57 patients with OCD were randomly allocated to receive escitalopram or sertraline. Yale Brown obsessive compulsive behavior scale (YBOCS) was used to assess the outcomes. Adverse effects were also recorded. 41 patients (20 in the escitalopram group and 21 in the sertraline group) completed the trial. In the escitalopram group 15 (70%) patients and in the sertraline group 16 (76.19%) patients showed more than 34% decrease in mean YBOCS score at the end of the trial (P=0.531). The two groups revealed significant decrease in YBOCS scores without significant difference (P=0.861) at week 12. No serious adverse effects were reported. Our results demonstrated that escitalopram is as effective as sertraline in treatment of obsessions and compulsions in patients with OCD. However, it needs to be noted that our study is preliminary and larger double blind controlled studies are needed to confirm the results.
ISSN:1876-2018
1876-2026
DOI:10.1016/j.ajp.2017.11.004